ea0073oc12.3 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | ECE2021
Simanenkova Anna
, Minasian Sarkis
, Karonova Tatiana
, Vlasov Timur
, Timkina Natalya
, Khalzova Aleksandra
, Shpilevaya Oksana
, Shimshilashvili Anzhelika
, Timofeeva Valeria
, Borshchev Yury
, Galagudza Mikhail
Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...